ClinicalTrials.gg
CompletedNCT06783166Updated Oct 26, 2026

Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure

A Phase 2/3 interventional study of Dapagliflozin 10mg and Acetazolamide 500mg in Acute Heart Failure, sponsored by Mansoura University. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Mansoura University · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Aug 2024, registered Jan 2025).
Updated Oct 26, 2026Now CompletedPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies testing dapagliflozin in Heart Failure — 15 open to participants now, 19 under way, 6 of them phase 3. dapagliflozin · Heart Failure.

Enrollment
24th of 59
108 · median 100
Started
2024
with 10 others
Phase 2/3
4 of 59
none open now
Registered
51st of 59
by date
Lead sponsor
2 of 59
Mansoura University

Among the 59 studies testing dapagliflozin in Heart Failure, this one is the 24th largest by enrollment, is one of 11 that started in 2024, is one of 4 in phase 2/3, and was the 51st registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

15 of the 59 studies testing dapagliflozin in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing dapagliflozin in Heart Failure, or all of them as a file.
02

Study summary

This study investigates the comparative clinical outcomes of dapagliflozin, an SGLT-2 inhibitor, versus acetazolamide, a carbonic anhydrase inhibitor, in patients hospitalized with acute heart failure (AHF). The trial aims to assess the effectiveness of these drugs in improving natriuretic and diuretic responses and shortening hospital stays. Dapagliflozin and acetazolamide will be added to standard loop diuretic therapy, and their safety profiles will be evaluated to identify potential side effects. This research seeks to provide evidence for incorporating these drugs into AHF management, with the potential to improve clinical outcomes.

03

Conditions studied

  • Acute Heart Failure

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 26, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18 years or older who are hospitalized for hypervolemic AHF, with evidence of congestion defined as either:

    • 2 of the following signs or symptoms: peripheral edema, ascites, jugular venous pressure > 10mmHg, orthopnea, paroxysmal nocturnal dyspnea, 5-pound weight gain, or signs of congestion on chest x-ray or lung ultrasound. OR
    • If pulmonary artery catheterization is available, a pulmonary capillary wedge pressure greater than 19 mmHg plus a systemic physical exam finding of hypervolemia from the list above.
  2. Randomized within 24 hours of hospitalization for AHF.
  3. Planned use of IV loop diuretic therapy during current hospitalization
  4. Estimated (eGFR) of at least 25 ml/min/1.73m2 by the MDRD equation.

Exclusion criteria

Exclusion Criteria:

  1. Unable to follow instructions.
  2. Treated with any proximal tubular diuretics.
  3. Systolic blood pressure of less than 90 mm Hg.
  4. An estimated (GFR) of less than 25 ml per 1.73 m2 of body-surface area.
  5. Type 1 diabetes mellitus.
  6. Dyspnea is primarily due to non-cardiac causes.
  7. Cardiogenic shock.
  8. Acute coronary syndrome within 30 days prior to randomization.
  9. Planned or recent percutaneous or surgical coronary intervention within 30 days prior to randomization.
  10. Signs of ketoacidosis and/or hyperosmolar hyperglycemic syndrome (pH>7.30 and glucose >15 mmol/L and HCO3>18 mmol/L).
  11. Pregnant or nursing (lactating) women.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    Dapagliflozin 10mg

    Patients will receive once daily dapagliflozin 10 mg orally in addition to loop diuretic therapy and standard care for 3 days.

    Drug: Dapagliflozin 10mg

  • Active comparator
    Acetazolamide 500mg

    Patients will receive once daily acetazolamide 500 mg orally in addition to loop diuretic therapy and standard care for 3 days.

    Drug: Acetazolamide 500mg

Interventions

06

What researchers measure

Primary outcomes

  1. Change in dyspnea VAS (Visual analogue scale)

    Comparing the area under the curve (AUC) of change in VAS dyspnea score. To do so, individual changes in VAS score will be visualized as a curve where the x-axis shows study day baseline to day 3, and y-axis shows VAS score. Using this approach, AUC for each study day will be calculated, and added together, resulting in an overall VAS AUC score (mm × h) that can be compared across treatment groups.

    Time frame: From baseline to day 3

07

Study locations

1 site
  • Noha Mansour
    Al Mansurah, Mansoura 35516, Egypt
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Jul 2025, 10 months.

Of 24 phase 2/3 interventional studies under Heart Failure, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 54. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2025
First posted
Jan 20, 2025
StartActual
Aug 15, 2024
Primary completionActual
Jul 4, 2025
CompletionActual
Aug 5, 2025
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 26, 2026
Sites
1 site added, 1 site removed
Show site
  • Noha Mansour · Al Mansurah, Egypt
Show 1 removed
  • Noha Mansour · Mansoura, Egypt
Oct 26, 2026
Primary completion
Jul 1, 2025→Jul 4, 2025 (actual)
Oct 26, 2026
Study completion
Aug 1, 2025→Aug 5, 2025 (actual)
Oct 26, 2026
Enrollment
100 (estimated)→108 (actual)
Oct 26, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedEstimated glomerular filtration rate (eGFR) of at least 3025 ml/min/1.73m2 by the MDRD equation.
Exclusion criteria
  • EditedAn estimated glomerular filtration rate (GFR) of less than 2025 ml per 1.73 m2 of body-surface area.
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Noha Mansour · Al Mansurah, Egypt
    Show 1 removed
    • Noha Mansour · Mansoura, Egypt
    Primary completion Jul 1, 2025→Jul 4, 2025 (now actual)
    Study completion Aug 1, 2025→Aug 5, 2025 (now actual)
    Enrollment 100 (estimated)→108 (actual)
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedEstimated glomerular filtration rate (eGFR) of at least 3025 ml/min/1.73m2 by the MDRD equation.
    Exclusion criteria
    • EditedAn estimated glomerular filtration rate (GFR) of less than 2025 ml per 1.73 m2 of body-surface area.
    + 4 other changes: verification date, design details, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06783166
Responsible party
Noha Mansour (Lecturer of Clinical Pharmacy, Mansoura University) — Principal investigator
First posted
Jan 20, 2025
Start date
Aug 15, 2024
Primary completion
Jul 4, 2025
Completion
Aug 5, 2025
Last update
Oct 26, 2026

Study contacts

Noha Mansour, PhD
principal investigator · Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, University of Mansoura
Moheb Magdy Mouris, MD
principal investigator · Department of Cardiology, Faculty of Medicine, University of Mansoura
Mohamed El- Husseiny Shams, Professor
study chair · Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, University of Mansoura

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion